Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T68934
(Former ID: TTDS00434)
|
|||||
| Target Name |
Collagen (CO)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 3 Target-related Diseases | + | ||||
| 1 | Amoebiasis [ICD-11: 1A36] | |||||
| 2 | Skin sensation disturbance [ICD-11: ME65] | |||||
| 3 | Vitamin deficiency [ICD-11: 5B55-5B5F] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 2 Approved Drugs | + | ||||
| 1 | Collagenase | Drug Info | Approved | Skin burns | [2], [3] | |
| 2 | Vitamin C | Drug Info | Approved | Vitamin C deficiency | [4], [5] | |
| Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
| 1 | MRG-201 | Drug Info | Phase 2 | Keloid | [6] | |
| Mode of Action | [+] 4 Modes of Action | + | ||||
| Breaker | [+] 1 Breaker drugs | + | ||||
| 1 | Collagenase | Drug Info | [1], [7] | |||
| Activator | [+] 1 Activator drugs | + | ||||
| 1 | Vitamin C | Drug Info | [8] | |||
| Modulator | [+] 1 Modulator drugs | + | ||||
| 1 | MRG-201 | Drug Info | [9] | |||
| Binder | [+] 1 Binder drugs | + | ||||
| 1 | Clostridial collagenase | Drug Info | [10] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Contact dermatitis with clostridiopeptidase A contained in Noruxol ointment. Contact Dermatitis. 2007 Jun;56(6):361-2. | |||||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||||
| REF 3 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||||
| REF 4 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4781). | |||||
| REF 5 | Vitamin C: update on physiology and pharmacology. Br J Pharmacol. 2009 Aug;157(7):1097-110. | |||||
| REF 6 | ClinicalTrials.gov (NCT03601052) Efficacy, Safety, and Tolerability of Remlarsen (MRG-201) Following Intradermal Injection in Subjects With a History of Keloids. U.S. National Institutes of Health. | |||||
| REF 7 | Interaction of collagen-related genes and susceptibility to betel quid-induced oral submucous fibrosis. Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):646-53. | |||||
| REF 8 | Effects of vitamin C on dark circles of the lower eyelids: quantitative evaluation using image analysis and echogram. Skin Res Technol. 2009 May;15(2):214-7. | |||||
| REF 9 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 10 | Collagen as a clinical target: nonoperative treatment of Dupuytren's disease. J Hand Surg Am. 2002 Sep;27(5):788-98. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.